The Department for Health and Social Care has asked NICE to conduct an appraisal of avatrombopag and lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing an elective procedure [ID1520]
Please note Avatrombopag was split from Lusutrombopag because a list price in the UK had not yet been agreed.
Lusutrombopag has now been recommended and guidance has been issued TA617.
Avatrombopag will now continue as a separate appraisal.